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ABSTRACT									ARTICLE INFO
______________________________________________________________

______________________

Introduction: The use of multi-parametric (MP) MRI to diagnose prostate cancer has
been the subject of intense research, with many studies showing positive results. The
purpose of our study is to better understand the accessibility, role, and perceived accuracy of MP-MRI in practice by surveying practicing urologists.
Materials and Methods: Surveys were sent to 7,400 practicing American Urological
Association member physicians with a current email address. The survey asked demographic information and addressed access, accuracy, cost, and role of prostate MRI in
clinical practice.
Results: Our survey elicited 276 responses. Respondents felt that limited access and
prohibitive cost of MP-MRI limits its use, 72% and 59% respectively. Academic urologists ordered more MP-MRI studies per year than those in private practice (43.3%
vs. 21.1%; p<0.001). Urologists who performed more than 30 prostatectomies a year
were more likely to feel that an MP-MRI would change their surgical approach (37.5%
vs. 19.6%, p-value=0.002). Only 25% of respondents agreed or strongly agreed that
MP-MRI should be used in active surveillance. For patients with negative biopsies and
elevated PSA, 39% reported MP-MRI to be very useful.
Conclusions: Our study found that MP-MRI use is most prominent among practitioners
who are oncology fellowship-trained, practice at academic centers, and perform more
than 30 prostatectomies per year. Limited access and prohibitive cost of MP-MRI may
limit its utility in practice. Additionally, study participants perceive a lack of accuracy
of MP-MRI, which is contrary to the recent literature.
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INTRODUCTION
Prostate cancer is the second leading cause
of cancer-related death in men, claiming almost
30.000 lives in 2013 (1). It is a heterogeneous disease with differences in biological aggressiveness, and the natural history of prostate cancer
is highly variable from patient to patient. It has
been shown that over half of those diagnosed with
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prostate cancer will die of other causes (2). In light of the United Service Preventative Task Force
recommendation against the use of prostate specific antigen (PSA) for cancer screening, as well as
several studies demonstrating no survival advantage with aggressive treatment, there has been a
growing interest in the use of active surveillance
in prostate cancer management (3). As the treatment algorithm for prostate cancer continues to

464

IBJU | PROSTATE MRI: UROLOGIST’S ATTITUDES AND PERCEPTIONS

evolve, there has been increased emphasis on the
use of multi-parametric magnetic resonance imaging (MP-MRI) to aid in the diagnosis and management of prostate cancer, especially within the
active surveillance population.
MRI provides high-resolution anatomic detail via T2 weighted images and allows for functional assessment of the prostate. Dynamic contrast
enhanced imaging measures the vascularity of tumors, and the vascular nature of prostate cancer
shows both increased uptake and washout of gadolinium contrast when given intravenously (4). Diffusion weighted imagining measures the diffusion
of water through tissue, causing prostate cancer
to exhibits reduced diffusion compared to normal
prostate tissue due to its densely packed cells.
Despite demonstration of the benefit within the literature, MP-MRI has been slow to gain
widespread acceptance (5). The practice patterns,
experience, and attitudes of American urologists
regarding the use of MRI in the management of
prostate cancer have not been previously examined. The goal of our study is to characterize the
opinions amongst current American urologists
concerning the role of MP-MRI in prostate cancer
management.
MATERIALS AND METHODS
This study was reviewed and approved by
the Institution Review Board at Washington University. A web-based survey consisting of twenty questions was developed and sent electronically to 7,400
current American Urological Association (AUA)
members. All survey participants were practicing
urologic physicians in the United States had current
email addresses as of September 01, 2013. An initial
email with a brief explanation of the study and an
invitation to complete the survey was sent on September 12, 2013, and a reminder email for those who
had yet to complete the survey was sent on September 25, 2013. Respondents were not required to
answer all questions for submission of their survey.
Each email was embedded with a personalized link
to ensure that each respondent could only submit a
single survey, and all responses were confidential.
Each survey was de-identified and responses were collected using our institutional RedCap

electronic data-capturing tool (6). Survey questions addressing practitioner demographics included: how many years since finishing residency,
post-residency training, proximity to nearest tertiary care center, structure of medical practice,
practice setting, and number of prostatectomies
performed yearly. Questions addressing practitioner opinion of MP-MRI included: evidence in literature supporting MP-MRI, reliability of the results
of MP-MRI, and accuracy of MP-MRI measured by
correlation between MP-MRI results and positive
biopsies/final pathology after prostatectomy.
Categorical responses to survey questions
were assessed using Chi-square test of independence analysis and Fisher’s exact test. Continuous
variables were compared with the Student’s t-test,
and statistical analyses were two-sided using a
significance of 0.05.
RESULTS
Our survey elicited 276 (3.8%) responses
from practicing AUA member physicians. Unfortunately, not all participants answered every survey
question. The demographics that were obtained
from the survey question can be found in Table-1.
Overall, a majority of survey participants reported
ordering 1-10 MP-MRIs a year to evaluate prostate
cancer. Forty-two percent of respondents agreed
that there was adequate evidence within the literature supporting the use of MP-MRI in localized
prostate cancer (114/272), 31% disagreed (84/272),
and 27% could not decide (74/272). A summary of
survey responses can be found in Table-2.
Access

When respondents were stratified by
their type of practice, there was a statistically
significant increase in the reported number of
MP-MRIs ordered by physicians who practice in
an academic setting compared those who do not
(>11 MP-MRIs/year, 43% versus 21% p=0.0001).
Eighty-nine percent of respondents endorsed
having local access (less than 1hr) to facilities with
MP-MRI capabilities (245/276). However, when all
respondents were asked if they felt that access to
qualified imaging centers and radiologists limited
their use of MP-MRI, 72% of respondents agreed or
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Table 1 - Survey Demographics.
Total = 276

How many years since you finished residency?
0-5 years

54 (19.5%)

6-10 years

39 (14.1%)

11-20 years

77 (27.8%)

21-30 years

77 (27.8%)

Over 31 years

29 (10.5%)
Total = 274

What training, if any, did you complete after residency?
None

159 (58%)

Minimal Invasive/Endourology Fellowship

21 (7.7%)

Oncology Fellowship

66 (24.1%)

Reconstructive Fellowship

9 (3.3%)

Other

19 (6.9%)

Approximately how close is the nearest tertiary care center to your practice?

Total = 276

I primarily practice at a tertiary care center

134 (48.6%)

Less than 1 hour

95 (34.4%)

Less than 2 hours

32 (11.6%)

Less than 3 hours

5 (1.8%)

More than 3 hours

10 (3.6%)
Total = 276

What type of practice do you work in primarily?
Private Group or Solo

164 (59.2%)

Academic

91 (32.9%)

Government (VA, Military service, National Health Service)

7 (2.5%)

Other

15 (5.4%)

What type of setting do you practice in?

Total = 276

Urban

151 (54.7%)

Suburban

103 (37.2%)

Rural

22 (8%)

On average, how many prostatectomies do you preform yearly for Prostate cancer?

Total = 275

Under 10

105 (38.2%)

30-Oct

85 (30.9%)

30-100

71 (25.8%)

Over 100

14 (5.1%)

strongly agreed (192/268). When asked if the cost
of MP-MRI was prohibitive for its use, 59% of all
respondents agreed or strongly agreed (156/263).
Role of MRI
Overall, 34% of respondents reported using
MP-MRI targeted biopsies, either ultrasound fu-

sion or cognitive techniques (91/270). When these
responses were stratified by fellowship training,
we found that respondents with oncology fellowship training performed significantly more MP-MRI targeted biopsies compared to those who did
not (44.6% versus 30.1%, p=0.032). In our survey, 38% of all respondents found MP-MRI to be
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Table 2 - Survey Responses.
There is adequate evidence supporting the use of MP-MRI to manage localized prostate cancer.

Total = 272

Agree

114 (42%)

Disagree

84 (31%)

Can not decide

74 (27%)

Access to MP-MRI limits my ability to use it in my practice.

Total = 268

Agree/Strongly agree

192 (72%)

Disagree/Strongly disagree

76 (28%)

The high cost of MP-MRI is prohibitive for its use.

Total = 263

Agree/Strongly agree

156 (59%)

Disagree/Strongly disagree

107 (41%)

MR-MPI guided biopsies are utilized in my practice.

Total = 270

Agree

91 (34%)

Disagree

179 (66%)

MP-MRI is helpful in patients with elevated PSA/abnormal prostate exam prior to biopsy.

Total = 270

Agree/Strongly agree

102 (38%)

Disagree/Strongly disagree

168 (62%)

MP-MRI is helpful in patients with negative biopsy and abnormal PSA/prostate exam.

Total = 225

Agree/Strongly agree

88 (39%)

Disagree/Strongly disagree

137 (61%)

MP-MRI is useful prior to definitive treatment with prostatectomy or radiation.

Total = 225

Agree/Strongly agree

32 (14%)

Disagree/Strongly disagree

193 (86%)

MP-MRI changes my treatment approach of intermediate/high risk prostate cancer.

Total = 253

Sometimes/often

66 (26%)

Rarely/never

187 (74%)

MP-MRI should be used in all patients for active surveillance.

Total = 276

Agree/Strongly agree

69 (25%)

Disagree/Strongly disagree

207 (75%)

How often do MP-MRI guided biopsies turn out to be positive?

Total = 233

Often/Very often

65 (28%)

Sometimes

77 (33%)

Rarely/Never

91 (39%)

How closely do MP-MRI results correlate with final pathology after prostatectomy?

Total = 233

Strong correlation

26 (11%)

Moderate correlation

145 (62%)

Weak correlation

46 (20%)

No correlation

16 (7%)
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helpful in a patient with an elevated PSA or abnormal prostate exam prior to biopsy (102/270).
When these responses where stratified by fellowship training, we found 48.2% of respondents
with oncology training found MP-MRI somewhat
or very helpful in this situation compared to
33.5% of respondents without oncology training.
This difference was found to be trending towards
significance with a p value of 0.057.
In patients with a negative biopsy and an
elevated PSA/abnormal prostate exam, 39% of all
respondents reported MP-MRI to be very helpful
(88/225). Fourteen percent of respondents reported MP-MRI to be very useful when utilized prior
to definitive treatment with either prostatectomy
or radiation (32/225). In patients with intermediate or high risk prostate cancer who appear to be
candidates for a nerve sparing prostatectomy, 26%
of respondents report that getting an MP-MRI will
sometimes or often change their surgical approach to a non-nerve sparing prostatectomy (66/253).
When stratified based on average number of prostatectomies performed per year (<30 versus >30);
we found that surgeons who perform more than
30 prostatectomies per year are more likely to
change their surgical approach based on MP-MRI
than those who perform less than 30/year (37%
versus 20%, p=0.002).
Regarding the use of MP-MRI in active
surveillance, 25% of all respondents agreed that
it should be used in all patients (69/276). When
asked if MP-MRI should be used to evaluate patients for active surveillance, 30.7% of respondents who were 10 years or less out of residency
reported MP-MRI to be very helpful compared to
24.8% of respondents 11 years or more out of residency (30/98 versus 45/183).
Accuracy
When asked approximately what proportion of patients with positive MP-MRI findings who subsequently undergo MP-MRI targeted
prostate biopsies are found to have biopsies positive for prostate cancer, 28% reported positive
biopsies “often” or “very often” (65/233), 33% reported positive biopsies “sometimes” (77/233), and
39% reported positive biopsies “rarely” or “never”
(91/233). Similarly, when asked about how closely

respondents find MP-MRI results to correlate with
final pathology after prostatectomy, 11% reported
strong correlation (26/233), 62% reported moderate correlation (145/233), 20% reported weak
correlation (46/233), and 7% reported no correlation (16/233).
DISCUSSION
The use of multi-parametric (MP-MRI) to
diagnose prostate cancer has been the subject of
intense research, with many studies showing positive results. To our knowledge, no other studies
have attempted to better understand the accessibility, role, and perceived accuracy of MP-MRI
in practice by surveying practicing urologists.
We found practicing in an academic center to be
strongly associated with increased use of MP-MRI
(p=0.0001), which is likely due to a combination
of increased access, familiarly with recent literature, and interdisciplinary efforts within academic
institutions.
Access

There is very little within the literature
evaluating practitioner access to MP-MRI, particularly outside academic centers. While 89% of
our respondents reported to be within one hour
of a facility with MP-MRI capabilities, 72% still
felt that their use of MP-MRI was limited by lack
of access. While the exact reasons for this discrepancy could not be gleaned from the survey data,
causes may relate to perceived lack of quality
in the MP-MRI provided, difficulty with patient
scheduling, or lack of strong multi-disciplinary
relationship with radiologists.
Another possible reason that MP-MRI has
been slow to gain wide spread popularity is that
many (59% within our study) feel that the cost of
these studies is prohibitive, and that issues surrounding insurance reimbursement negate the
perceived value of the study. As the presence of
MP-MRI becomes stronger in national and international management guidelines, insurance approval and payment for these studies may become
more streamlined (7-9). Likewise, as the guidelines
for active surveillance continue to evolve, MP-MRI may be incorporated into these algorithms,
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which will support this study as a reimbursable
indication.
Role

The use of MP-MRI in the management
of prostate cancer has gained a lot of attention
in recent literature; however, the appropriate
use in clinical practice has not yet been established. Despite the growing body of evidence supporting the use of MP-MRI guided biopsies in
lieu of saturation biopsies, many of our respondents did not echo this sediment. We found that
only 42% of respondents felt that the current
literature provided evidence for some role for
MP-MRI in localized prostate cancer patients,
while 31% disagreed and 27% could not decide.
These results further prove the level of controversy surrounding MP-MRI.
MP-MRI can be used to provide guidance for tissue sampling either directly, via a cognitive approach, or through fusion software. MP-MRI guided biopsies have been shown to upgrade
Gleason grade and detect otherwise undiagnosed
anterior gland tumors in a significant number of
patients (10-13). Despite this, only 34% of respondents reported using MP-MRI guided biopsies in
their clinical practice. However, level of training
was found to be associated with an increased use
of MP-MRI guided biopsies. Completion of an oncology fellowship resulted in statistically significant increases in usage (p=0.032), and completion
of any urologic fellowship also trended towards
a significant increase (p=0.057). While this may
be in part due to the fact that many of these urologists practice at academic centers, these results
suggest that further training and education on
MP-MRI guided biopsies may be useful to guide
practice.
In intermediate or high-risk prostate cancer patients who appear to be candidates for a nerve sparing prostatectomy, MP-MRI can be helpful
for surgical planning (14-15). Of our respondents,
38% found MP-MRI to be helpful when used in this
capacity. We also found those urologists who reported doing more than 30 prostatectomies a year
used MP-MRI for surgical or treatment planning
at a higher frequency compared to their colleagues (p=0.002). It is possible that urologists with

more operative experience may have increased
expertise and familiarity with MP-MRI. It is also
possible that they handle more complex cases, requiring the use of additional imaging modalities.
It has also been proposed to incorporate
MP-MRI into active surveillance protocols (16-17).
While the majority of current evidence suggests a
benefit to its incorporation, there have been some
studies that failed to demonstrate an improvement
in the stratification of patients (18-19). In our study, only 25% of all respondents agreed or strongly
agreed that MP-MRI should be used in all patients
on active surveillance. In patients with a previous
negative biopsy and a rising PSA or abnormal DRE
there are several studies that have found MP-MRI
to be helpful and this has been incorporated in to
many current guidelines (7-9, 20-21). Despite this,
only 39% of respondents in our study agreed that
MP-MRI was helpful or very helpful for these patients. Reasons for this disconnect may be related
to the dissemination of this information to practicing urologists or perceived poor performance of
MRI in practice.
Accuracy
While several studies have shown the high
accuracy of MP-MRI, respondents seemed to largely express skepticism (13, 22-23). There were
a large proportion of respondents who felt that
MP-MRI was relatively inaccurate, with moderate-poor correlation with pathology and little positive impact on patient care. While the reason for
these opinions was not elucidated in our study,
this negative impression of MP-MRI may reflect
differences in local radiologist and pathologist
ability to interpret and correlate MP-MRI findings.
It is well accepted that achieving accurate radiology-pathology correlation with MP-MRI findings is
challenging, and it has been suggested that standardization of protocols is the best way to overcome these challenges (24-25). The European Society
for Urogenital Radiology has developed guidelines
to standardize reporting and acquisition of prostate MRIs, named the Prostate Imaging Reporting
and Diagnostic System (PI-RADS) (8). Unfortunately, this system has not been universally adopted in the United States. Further standardization
may help to ensure that the use of MP-MRI in the
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community mirrors the same accuracy and provides the same patient benefits as those reported
in the literature. As urologists are able to master
this learning curve, one would expect accuracy to
improve.
There are several limitations to our study. The response rate of only 3.8% is clearly less
than ideal, and it would have been preferable if all
respondents had answered every survey question.
Never the less, with 276 respondents exhibiting
a wide range of demographics, we feel that the
responses provide an adequate sample size. The
survey was designed to provide data that could be
easily analyzed, yet multiple choice answers carry
the risk of being leading. It might be anticipated
that the survey would have promoted a bias toward MP-MRI, yet the results indicate otherwise.
Further directions for research include a survey
administered to a large number of practitioners
across different vendor platforms and in various
institutional settings. Also, it would be helpful to
obtain insight into why practitioners chose their
various answers, would could be accomplished
with a more in-depth amended to include the option for free response.
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